Mortality and HRQoL in ICU patients with delirium: Protocol for 1-year follow-up of AID-ICU trial

Camilla B Mortensen, Lone M Poulsen, Nina C Andersen-Ranberg, Anders Perner, Theis Lange, Stine Estrup S, Bjørn H Ebdrup, Ingrid Egerod, Bodil S Rasmussen, Johanna Hästbacka, Jesús Caballero, Giuseppe Citerio, Matthew P G Morgan, Karin Samuelson, Ole Mathiesen

Research output: Contribution to journalArticleScientificpeer-review

3 Citations (Scopus)

Abstract

BACKGROUND: Intensive care unit (ICU)-acquired delirium is frequent and associated with poor short- and long-term outcomes for patients in ICUs. It therefore constitutes a major healthcare problem. Despite limited evidence, haloperidol is the most frequently used pharmacological intervention against ICU-acquired delirium. Agents intervening against Delirium in the ICU (AID-ICU) is an international, multicentre, randomised, blinded, placebo-controlled trial investigates benefits and harms of treatment with haloperidol in patients with ICU-acquired delirium. The current pre-planned one-year follow-up study of the AID-ICU trial population aims to explore the effects of haloperidol on one-year mortality and health related quality of life (HRQoL).

METHODS: The AID-ICU trial will include 1000 participants. One-year mortality will be obtained from the trial sites; we will validate the vital status of Danish participants using the Danish National Health Data Registers. Mortality will be analysed by Cox-regression and visualized by Kaplan-Meier curves tested for significance using the log-rank test. We will obtain HRQoL data using the EQ-5D instrument. HRQoL analysis will be performed using a general linear model adjusted for stratification variables. Deceased participants will be designated the worst possible value.

RESULTS: We expect to publish results of this study in 2022.

CONCLUSION: We expect that this one-year follow-up study of participants with ICU-acquired delirium allocated to haloperidol vs. placebo will provide important information on the long-term consequences of delirium including the effects of haloperidol. We expect that our results will improve the care of this vulnerable patient group.

Original languageEnglish
Pages (from-to)1519-1525
Number of pages7
JournalActa Anaesthesiologica Scandinavica
Volume64
Issue number10
DOIs
Publication statusPublished - Nov 2020
Externally publishedYes
Publication typeA1 Journal article-refereed

Keywords

  • Critical Care
  • Delirium/drug therapy
  • Follow-Up Studies
  • Humans
  • Intensive Care Units
  • Quality of Life

Fingerprint

Dive into the research topics of 'Mortality and HRQoL in ICU patients with delirium: Protocol for 1-year follow-up of AID-ICU trial'. Together they form a unique fingerprint.

Cite this